Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pyrotinib - Jiangsu Hengrui Medicine

Next Previous
Drug Profile

Pyrotinib - Jiangsu Hengrui Medicine

Alternative Names: BLTN; Irene; Pyrotinib maleate; Pyrroltinib maleate; SHR 1258

Latest Information Update: 11 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Developer Chinese Academy of Medical Sciences; Fudan University; Jiangsu Hengrui Medicine Co.; Peking Union Medical College Hospital; Shanghai Changzheng Hospital; Sun Yat-Sen University; Tongji University
  • Class Antineoplastics; Pyridines; Pyrrolidines; Quinolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HER2 positive breast cancer
  • Phase III Non-small cell lung cancer
  • No development reported Colorectal cancer; Gastric cancer; Urogenital cancer

Most Recent Events

  • 10 Dec 2024 Efficacy and adverse events data from phase III PHILA trial in HER2-positive Breast cancer presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
  • 13 Sep 2024 Efficacy and adverse event data from a phase II trial in Breast cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 13 Sep 2024 Efficacy and adverse event data from the phase II trial for HER2 positive Breast cancer presented at the 49th European Society for Medical Oncology Congress 2024 (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top